The impact of anhedonia on physical health and somatic diseases: an exploratory literature review

EUROPEAN NEUROPSYCHOPHARMACOLOGY · Published 2026-07-20 · DOI 10.1016/j.euroneuro.2026.112902

Free full text

Authors (11)

Koen Demyttenaere, Mohammed Alassiry, Anna Bobrowska, Andrea Fagiolini, Philip Gorwood, Yerkebulan Kambarov, Samer Makhoul, Andreas Reif, Jesper Riise, Tamara Werner-Kiechle, Roger S. McIntyre

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Demyttenaere, K., Alassiry, M., Bobrowska, A., et al. (2026). The impact of anhedonia on physical health and somatic diseases: an exploratory literature review. EUROPEAN NEUROPSYCHOPHARMACOLOGY. https://doi.org/10.1016/j.euroneuro.2026.112902

Related articles

• Effectiveness of GLP-1RA vs metformin for diabetes prevention in antipsychotic-treated patients · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Complexity or simplicity? A replication analysis of low heart rate as a predictor of TMS response in major depressive disorder · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• A call for the systematic assessment of sexual adverse events in ketamine and esketamine trials and clinical practice · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• When clinical trials fail to represent patients: implications for schizophrenia guidelines · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Prevalence and outcomes of co-occurring psychiatric and neurological disorders: An atlas based on umbrella review of 81 meta-analyses · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Involuntary movements integral to psychotic illness: a ‘circular epistemological journey’ informing the pathobiology and treatment of psychosis and reconceptualising tardive dyskinesia · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Rethinking neurocognitive and cardiometabolic screening in severe mental illness · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal
• Dissecting the shared genetic architecture of ADHD and substance use disorders: Promising leads and persistent challenges · EUROPEAN NEUROPSYCHOPHARMACOLOGY · 2026 · Same journal